An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols

Conditions

• Advanced Solid Tumors

Interventions

• DRUG: Tivantinib
• DRUG: Anti-Cancer Combination Therapy

Sponsor

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)